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ABSTRACT 
 
 
The transcription factor NF-κB has been shown to inhibit the differentiation of 
skeletal muscle cells via numerous molecular mechanisms [1-4] and is believed to 
play an integral role in several skeletal myopathies [3, 5].  NF-κB has also been 
shown to play a vital role in inhibiting programmed cell death by up-regulating 
specific anti-apoptotic genes following a stressful stimulus [6-8].  Interestingly, it has 
been reported that terminally differentiated skeletal muscle cells devoid of NF-κB 
activity do not undergo apoptosis when treated with the inflammatory cytokines 
interferon-γ and tumor necrosis factor alpha (TNFα) [3].  In this study, we examine 
the reported phenomenon using TNFα, an extrinsic signal for apoptosis as well as a 
potent activator of NF-κB, to better determine the role of NF-κB in the survival of 
skeletal muscle cells at different stages of the differentiation program.  Using a 
C2C12 cell line stably expressing a plasmid coding for a dominant negative form of 
IκBα (IκBα-SR), it was shown that myoblasts lacking competent NF-κB activity were 
sensitized to TNFα-induced apoptosis, while identical IκBα-SR myotubes were not.  
To determine if C2C12 myotubes possess an intact TNFα signaling pathway, Western 
blotting for phosphorylated forms of p38 and JNK as well as reverse transcriptase-
PCR for TNFα-activated genes were performed.   It has recently been claimed that 
skeletal muscle differentiation evokes a natural reduction of apoptotic peptidase 
activating factor-1 (Apaf-1), a vital pro-apoptotic protein [9].  Western blot analysis 
of ΙκΒα-SR myoblasts and myotubes confirm that the natural reduction of Apaf-1 is 
present in C2C12 cultures, as well as indicate that the reduction is not dependent on 
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NF-κB.  To determine if this reduction in Apaf-1 could be the mechanism responsible 
for the NF-κB independent inhibition of apoptosis seen in skeletal myotubes, C2C12-
IκBα-SR myoblasts were transiently transfected with an Apaf-1 expression plasmid 
and differentiated before being treated with TNFα.  The over-expression of Apaf-1 in 
IκBα-SR myotubes did not rescue sensitivity to TNFα-induced apoptosis, as 
measured by levels of cleaved caspase-3 following treatment.  Collectively, these 
findings indicate that the transcription factor NF-κB is vital to the survival of skeletal 
myoblasts, but not required to inhibit TNFα-induced apoptosis in skeletal myotubes.  
Additionally, we show that the reduction of Apaf-1 along the myogenic program is 
not required for the survival of terminally differentiated skeletal myotubes treated 
with TNFα.   Future elucidation of the role of NF-κB and important anti-apoptotic 
mechanisms in mature skeletal muscle could lead to a better understanding of skeletal 
muscle differentiation as well as novel insight into numerous skeletal muscle 
diseases, including the pediatric muscle cancer rhabdomyosarcoma. 
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CHAPTER 1 – INTRODUCTION 
 
 
1.1 - Problem Statement and Significance 
 
Skeletal muscle cell differentiation is the process by which mononucleated, 
proliferative myoblasts fuse to form multinucleated, contractually-competent muscle cells 
called myotubes [10].  In vivo this differentiation process is completed around the time of 
birth, and myotube regeneration can be a very arduous process [11].  Because of the 
strenuous demand of regeneration, it is an advantage for the organism to maintain a stable 
number of skeletal muscle cells.  In line with this idea, mature skeletal muscle is 
observed as a very death-resistant tissue [12].   However, currently very little is known 
about the molecular mechanisms that account for this “hardy” phenotype.   
One suggested mechanism for this hardiness is through differentiation’s 
regulation of apoptotic peptidase activating factor-1 (Apaf-1).  Apaf-1 is a pro-apoptotic 
protein located in the cytoplasm and found to be integral to most forms of apoptosis 
through its role in the apoptosome, a cytoplasmic protein complex composed of Apaf-1, 
cytochrome C, and procaspase-9 [13].  During skeletal muscle differentiation, the levels 
of Apaf-1 decrease significantly and are thought to greatly impair the myotubes ability to 
undergo programmed cell death as induced by the protein cytochrome C [9].   However, 
cytochrome C is not a readily occurring stimulus for apoptosis.  It is located in the matrix 
of the mitochondria and used in the electron transport chain to produce ATP; it must be 
induced by another stimulus or stress signal to be released into the cytoplasm [13].   
The inflammatory cytokine tumor necrosis factor alpha (TNFα) is one such 
stimulus [14].  Interestingly, TNFα has also been shown to be a key mediator in skeletal 
myopathies such as cachexia and muscular dystrophy [3, 5].  The cellular protein through 
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which TNFα exerts its deleterious effect in these diseases is NF-κB, a potent inhibitor of 
both differentiation [1-4] and apoptosis [6-8].  The response of skeletal muscle cells to 
TNFα during the differentiation process and the role of NF-κB in myotube survival could 
not only provide new information about skeletal muscle development and physiology, but 
it could also lead to new insight in the mechanisms of many skeletal myopathies.   
 
 
1.2 - Background Information 
 
NF-κB is a transcription factor from the Rel family of transcription factors.  
Currently, there are five known mammalian Rel proteins: RelA (p65), c-Rel, RelB, p50 
and p52.  These proteins are subunits of NF-κB and exist in cells as homodimers or 
heterodimers.  The p65/p50 heterodimer is the NF-κB form shown to inhibit 
differentiation as well as apoptosis and will from here on be referred to as “NF-κB” [15]. 
In unstimulated cells, NF-κB is inactive and bound to an IκB family protein, 
specifically IκBα.  IκBα traps the transcription factor in the cytoplasm by blocking 
important phosphorylation sites and the nuclear localization signal of the dimer.  Because 
of this, the IκB protein must be degraded before NF-κB can be activated and translocate 
to the nucleus [15].  To degrade, IκBα must first be phosphorylated at serine residues 32 
and 36.  This phosphorylation tags the protein for polyubiquitination and, ultimately, 
degradation by the proteasome [15].    
NF-κB is activated by many signals, including hypoxic conditions, ionizing 
radiation, cell stress, and inflammatory cytokines [15].  Once activated, NF-κB enters the 
nucleus and promotes the transcription of a vast assortment of genes involved in 
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numerous of biological processes, including skeletal muscle differentiation and apoptotic 
regulation [15]. 
Studies have reported several mechanisms by which NF-κB is an inhibitor of 
apoptosis [6-8, 16].  Apoptosis, or programmed-cell death, is characterized by membrane 
blebbing, chromatin condensation, nuclear fragmentation, and an overall reduction in 
cellular volume [17].  Mechanistically, apoptosis occurs as a result of intrinsic or 
extrinsic stimuli that trigger the systematic production and activation of caspases, 
proteases that dismantle the cell through the cleavage of intracellular substrates [17]. 
One such extrinsic apoptotic signal is the inflammatory cytokine TNFα.  To signal 
apoptosis, TNFα binds to and causes the trimerization of TNF receptor-1 (TNFR1) [14].  
TNFR1 trimerization signals the eventual formation of the death-inducing signaling 
complex (DISC), also know as complex II.  This cytoplasmic complex consists of TNF-
receptor associated factor 2 (TRAF2), TNF-receptor associated death domain (TRADD), 
Fas-associated death domain (FADD), the kinase RIP1, and the progenitor forms of 
caspases-8 and -10 [18]. The formation of DISC results in the cleavage of procaspases-8 
and -10 to their activated counterparts.  Caspases-8 and -10 then cleave a protein called to 
Bid to a truncated form (tBid), which interacts with anti-apoptotic Bcl-2 family proteins 
and results in the release of cytochrome C from the mitochondrion [19-21].  Cytoplasmic 
cytochrome C binds with procaspase-9 and Apaf-1 in an ATP-dependent manner to form 
a molecular machine known as the apoptosome [19-21].  Once activated, caspase-9 
cleaves the effector caspase, caspase-3.  Caspase-3 then activates caspase-activated 
deoxyribonuclease (CAD) by cleavage of the enzyme’s inhibitor domain, allowing CAD 
to enter the nucleus and degrade chromosomal DNA [19-21]. 
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 Paradoxically, an hour before the DISC complex forms, TNFα signals the 
formation of a different multi-protein complex.  This complex, termed complex 1, forms 
directly on the activated, membrane-bound TNFR1 and signals the activation of NF-κB 
[18, 20-21].  Complex 1 is comprised of TNFR1, TRAF2, TRADD, and RIP1, the kinase 
believed to be responsible for the TNFα-dependent stimulation of the inhibitor of κB 
kinase (IKK) complex [18].  The IKK complex then phosphorylates IκBα leading to its 
degradation and the subsequent activation of NF-κB [18].  NF-κB activation leads to an 
increase in the transcription of NF-κB regulated genes, including the anti-apoptotic 
genes, cIAP1, cIAP2, Bcl-xL, A1, and XIAP [20-21].  These genes transcribe proteins that 
inhibit the TNFα-induced apoptotic cascade at various points (Appendix A.1).  Because 
complex 1 forms an hour before the DISC complex and up-regulates the transcription of 
anti-apoptotic genes through NF-κB, TNFα alone does not kill most healthy, wild-type 
cells.  However, in cells lacking competent NF-κB activity, TNFα is a potent apoptotic 
agent [6-8].   
In skeletal muscle cells, NF-κB also plays a role in regulating differentiation.  
Differentiation is the process through which a cell transforms from less tissue specific to 
more tissue specific; this transformation is characterized by an exit from the mitotic cell 
cycle [22].  NF-κB inhibits this differentiation process by trapping the cell in the 
replicative cycle [1-2] and inhibiting the production of muscle-specific genes, through 
both transcriptional repression and post-transcriptional modification [3-4].   
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1.3 - Objectives 
 
 It was previously reported that NF-κB is an important molecular mediator of 
muscle cachexia [3] and an inhibitor of skeletal muscle differentiation [1-4].  However, in 
one study [3], it was observed that C2C12 myotubes lacking NF-κB activity (via a stable 
infection of a dominant negative IκBα mutant IκBα-SR) do not exhibit morphological 
signs of cell death following TNFα treatment.   
 Our objective for this study was to investigate the role of skeletal muscle 
differentiation on the molecular machinery responsible for carrying out TNFα-induced 
apoptosis.  Particular interest was taken in NF-κB independent mechanisms of apoptotic 
inhibition, including the proposed down-regulation of the pro-apoptotic protein Apaf-1 
that occurs during differentiation [9].   
 
Confirm the lack of TNFα-induced apoptosis in C2C12 IκBα-SR myotubes. 
The first aim of this study was to replicate previous findings [3] that C2C12 
myotubes did not require NF-κB to inhibit TNFα-induced apoptosis.  Additionally, we 
sought to confirm that NF-κB was vital to C2C12 myoblast survival against TNFα 
stimulation and that TNFα treatment induced apoptosis in the absence of functional NF-
κB signaling.   
 
Confirm the presence of a fully functional TNFα signaling pathway in C2C12 
myotubes.  
  
Next, we wanted to confirm that differentiated C2C12 cells were able to 
functionally sense the inflammatory cytokine TNFα.  If the cytokine was not properly 
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received by TNFR1, then the absence of apoptosis in IκBα-SR myotubes could simply be 
due to the differentiated cell’s insensitivity to TNFα.   
 
Investigate the effects of differentiation and NF-κB inhibition on the pro-apoptotic 
protein Apaf-1. 
 
 It was recently proposed that skeletal muscle differentiation evokes a natural 
reduction of Apaf-1 [9], but as of yet, very little is known about anti-apoptotic 
mechanism.  By investigating this phenomenon in the absence of the NF-κB, the possible 
role of this transcription factor in Apaf-1 reduction can be examined.  If NF-κB appeared 
to play no direct role in the event, it could be hypothesized that the natural reduction of 
Apaf-1 during differentiation was at least partially responsible for the NF-κB independent 
inhibition of apoptosis seen in skeletal myotubes. 
 
Determine the role of the Apaf-1 in TNFα-induced myotube apoptosis.  
 Finally, we sought to better determine the role of Apaf-1 in TNFα-induced 
apoptosis in C2C12 myotubes by transfecting C2C12 Vector and IκBα-SR cells with an 
Apaf-1 expression plasmid.  Once these cells were transfected to over-express Apaf-1, 
they could be differentiated to form myotubes, treated with TNFα, and examined for 
markers of apoptosis.   
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CHAPTER 2 - MATERIALS AND METHODS  
 
 
Cell Culture 
Murine C2C12 skeletal myoblasts were cultured in 5% CO2 at 37°C in Dulbecco’s 
modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin. The cells were grown below confluency and passaged 
every 3 to 4 days. To induce differentiation, the cells were grown overnight to 50 to 60% 
confluency in growth medium (GM), washed once with phosphate-buffered saline (PBS), 
and then switched to DMEM supplemented with 2% horse serum and 10 mg of insulin 
per ml plus antibiotics (differentiation medium or DM).  Stable cell lines expressing the 
mutant dominant negative IκBα protein (IκBα-SR) and the control vector cell line were 
prepared as previously described [1].  All media and other cell culture reagents were 
purchased from GIBCO-Invitrogen (California, United States). 
 
Nuclear Extracts 
Cells grown in 100 mm diameter dishes were washed twice with phosphate-buffered 
saline, gently scraped from the plates, transferred to microcentrifuge tubes, and lysed on 
ice in cytoplasmic extraction buffer (10 mM HEPES [pH 7.6], 60 mM KCl, 1 mM 
EDTA, 0.1% Nonidet P-40). Nuclei were pelleted (2600 rpm, 4°C, 4 min).  Nuclei were 
washed gently with 100 ml of cytoplasmic extraction buffer without Nonidet P-40 and 
pelleted (2600 rpm, 4°C, 4 min). Nuclear extraction buffer (20 mM Tris [pH 8.0], 420 
mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 25% 
glycerol) was added to the pellets.  Nuclear pellets were then resuspended by vortexing, 
and the nuclear lysates were maintained on ice for 10 min with additional periodic 
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vortexing. Nuclear extracts were cleared (13,200 rpm, 4°C, 10 min) and transferred to 
fresh tubes. Protein concentrations were determined by optical densitometry using the 
Bradford assay and all extracts were stored at -80°C. 
 
Electrophoretic Mobility Shift Assay 
5 μg of nuclear extract was pre-incubated with 50 mM phenylmethylsulfonyl fluoride and 
1 μg poly(dI-dC) (Amersham Biosciences) for 10 minutes at room temperature.  This 
mixture was then incubated with 20,000 cpm of a 32P-labeled oligonucleotide probe 
containing an NF-κB binding site in a total volume of 20 μl binding buffer for 20 minutes 
at room temperature.  The binding buffer was made up of 50 mM Tris-HCl (pH 7.6), 2.5 
mM EDTA, 5 mM dithiothreitol, and 50% glycerol.  Protein-oligonucleotide complexes 
were resolved on a 5% acrylamide gel in TGE buffer (25 mM Tris, 190mM glycine, and 
1 mM EDTA) at 25 mA for 2.5 hours.  The gel was dried and exposed on a 
phosphoscreen overnight before being scanned on a Typhoon scanner (Amersham 
Biosciences).   
 
Luciferase Assay 
Cells were grown to 50% confluency in 12 well plates and cotransfected with 0.250 μg 
3xκB-Luc [1], a reporter plasmid containing 3 NF-κB binding sites in front of the 
luciferase gene, and 0.250 μg CMV-LacZ, a reporter plasmid used to monitor transfection 
efficiency, using Lipofectamine reagent (Invitrogen). Plasmids were incubated in Opti-
Mem medium with Lipofectamine and Plus Reagent (Invitrogen) for 30 minutes before 
being added to cells in 1 ml Opti-Mem.  Cells were incubated in transfection medium for 
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2 to 3 hours, washed in PBS, and allowed to grow overnight in GM.  The cells were then 
treated, washed in PBS, and collected using M-PER reagent (Pierce).  Luciferase assays 
were performed using 40 μl of cell lysate in a white 96-well plate with 1 mM luciferin 
substrate on a Veritas Luminometer.  Transfection efficiency was measure by β-
galactodiose assay with optical densitometry using ONPG as a substrate. 
 
Western Blot Analysis 
Cells were harvested in PBS, and whole-cell lysates were prepared by suspending cell 
pellets in ice-cold RIPA buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 1% sodium 
dodecyl sulfate [SDS], 1% Nonidet P-40) and incubating the suspension on ice for 10 
min. For Western blots of phosphorylated proteins, lysis buffer included phosphatase 
inhibitors (50 mM sodium fluoride, 1 mM orthovanadate, 50 mM b-glycerophosphate, 80 
mM cantharidin). Supernatant lysates were collected following high-speed centrifugation 
(5,000 rpm) for 5 min at 4°C.  Equal amounts of protein extract, as determined by protein 
optical density measurement via the Bradford assay, were subjected to SDS-
polyacrylamide gel electrophoresis and transferred to methanol-activated polyvinylidene 
fluoride membranes (Millipore). Blocking was performed in 5% nonfat dry milk TBST 
(25 mM Tris-HCl [pH 8.0], 125 mM NaCl, 0.1% Tween 20). Primary antibodies were 
diluted in 3% bovine serum albumin TBST and membranes incubated at 4oC overnight.  
Secondary antibodies were diluted in 0.5% nonfat dry milk TBST and incubated for 1 
hour at room temperature.  Washes were performed in TBST for 5 to 10 min and repeated 
three times between incubations. Specific protein bands were visualized by enhanced 
chemiluminescence (Perkin Elmer). Antibodies to cleaved caspase-3, phospho-p38, p38, 
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and myogenin were obtained from Santa Cruz Biotechnology (California, United States), 
Apaf-1 antibody obtained from Alexis Biochemicals (California, United States), and α-
tubulin antibody was procured from Sigma Aldrich (Missouri, United States).  Secondary 
mouse and rabbit antibodies were obtained form Promega (Wisconsin, United States); 
secondary rat antibody was obtained from Alexis Biochemicals (California, United 
States). 
 
Cell Counting and Phase Microscopy 
Cells were cultured in 12-well plates and grown to 60-70% confluency following 
previously mentioned guidelines.  Cells were photographed on an Olympus CK40 phase 
contrast microscope using a Nikon Coolpix 4500 with special microscope lens 
attachment.  Following photographic documentation, cells were washed in PBS and 
incubated in 0.25% trypsin with EDTA (GIBCO-Invitrogen) for 4 minutes to remove 
cells from plate.  Trypsinized cells were then resuspended in GM.  Approximately 10 μl 
of cell suspension was then loaded into each side of a hemocytometer and cells were 
counted using previously listed phase contrast microscope.  Cell suspension count was 
then multiplied by dilution factor to get the final cell count. 
 
TUNEL Assay and Immunofluorescent Staining 
All terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) experiments 
were performed directly in 35 mm dishes using the “In Situ Cell Death Detection Kit, 
Fluorescein” from Roche Applied Sciences (Indiana, United States).  Myoblasts and 
myotubes were cultured then treated with TNFα from Roche at the listed concentrations 
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and time periods.   Media was removed and cells were washed with PBS.  Cells were 
then fixed with 4% paraformaldehyde for 1 hour at room temperature then rewashed with 
PBS.  Cells were incubated in permeabilisation solution (0.1% Triton X-100 in 0.1% 
sodium citrate) for two minutes on ice.  After a PBS wash and once dry, the sample was 
treated with TUNEL reaction mixture for 1 hour at 37oC in a dark, humid incubator.  The 
cells were washed 3x with PBS and permeabilized in 0.5% NP-40 for 5 minutes.  
Samples were washed twice with PBS and blocked for 30 minutes in horse serum (1:100 
in PBS).  Following two more PBS washes, the cells were incubated with myosin-heavy 
chain antibody (Santa Cruz, 1:500) in 3% BSA for 1 hour.  Cells were then washed three 
times in PBS and incubated with secondary antibody (Molecular Probes, 1:250 in 
3%BSA) for one hour.  Samples were washed with PBS and dionized water, then 
coverslipped.  Samples were examined by fluorescence microscopy. 
 
Transient Transfection 
Cells were grown to 50% confluency in 60 mm dishes transfected with 2.5 μg of either a 
plasmid containing the Apaf-1 gene linked to a CMV promoter (Invitrogen) or an empty 
CMV-linked pCDNA3 vector plasmid.  Plasmids were allowed to incubate in 0.5 ml 
Opti-Mem medium with Lipofectamine and Plus Reagent (Invitrogen) for 30 minutes 
before being added to cells in 2 ml Opti-Mem.  Cells were incubated in transfection 
medium for 2 to 3 hours, washed in PBS, and allowed to grow overnight in GM.  
Following overnight incubation, cells were washed and switched to DM for 72 hours 
before being collected. 
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Reverse Transcriptase-PCR 
RNA was isolated with Trizol Reagent per the manufacturer’s recommendations (Life 
Technologies).  5 μg of RNA isolated from cells under differing treatment conditions was 
converted to cDNA using M-MLV reverse transcriptase (Invitrogen) and 
recommendations of the manufacturers.  cDNA mixture was then diluted with 80 μl 
DEPC-H2O and 2 μl was used as a template in a PCR with Taq DNA polymerase (New 
England Biolabs) using the following primer pairs: 
cIAP:  Forward – 5’-GCTTCTACTACATAGGACCTGG-3’ 
 Reverse – 5’-CACTTGACATCATCACTGTGTCC-3’ 
 
GAPDH:  Forward – 5’-CAGGGCAAATTCAACGGCACAGTCAAGG-3’ 
      Reverse – 5’-GTTCACACCCATCACAAACATGG-3’ 
 
PCR mixture samples were run on an ethidyum-bromide spiked agarose gel and viewed 
using an AlphaImager (Alpha Innotech). 
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CHAPTER 3 - RESULTS 
 
 
3.1 - Inhibition of NF-κB in C2C12 cell line via IκBα-SR expression 
 
The stable C2C12 murine myoblast cell lines used for this investigation, one 
expressing a dominant negative form of IκBα called IκBα-super repressor (IκBα-SR) and 
the other an empty vector plasmid (Vector), were previously created by retroviral 
infection [1].   This dominant negative form of IκBα cannot be phosphorylated properly 
due to mutations at serine residues 32 and 36 [15].  The loss of these phosphorylation 
sites on IκBα inhibits activation of NF-κB by preventing ubiquitin-mediated degradation 
by the proteasome.  Without the IκBα degradation, NF-κB is trapped in the cytoplasm 
and unable to regulate transcription (Diagram A.2).   
To verify the inhibition of NF-κB in the C2C12 IκBα-SR cell line, two 
experiments were performed (Figure B.1).  First, to show the cytoplasmic trapping of NF-
κB, a gel shift was performed (Figure B.1 - A).  C2C12 Vector myoblasts exhibited basal 
levels of activated NF-κB as well as increased levels following both 15 and 30 minutes of 
TNFα treatment.  Both treated and untreated C2C12 IκBα-SR myoblasts exhibited no 
levels of activated, nuclear NF-κB. 
Functional inhibition of NF-κB was verified by luciferase assay using transient 
transfection of the 3xκB-Luc plasmid [1] (Figure B.1 – B).  C2C12 Vector myoblasts 
exhibited a TNFα dependent increase in luciferase activity, while C2C12 IκBα-SR 
myoblasts had only negligible levels of luciferase activity and were unaffected by TNFα 
treatment.  This absence of TNFα induced luciferase activity indicates that C2C12 IκBα-
SR cells have a loss of NF-κB dependent transcriptional activity. 
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3.2 - IκBα-SR myoblasts are sensitive to TNFα-induced apoptosis 
 
In previous studies [3], myotubes expressing the mutant IκBα-SR protein have 
been treated with TNFα to show that NF-κB positively regulates cachexia.  While such 
experiments have shown that myotubes devoid of NF-κB activity do not undergo 
cachectic degradation, the experiments have also shown that such myotubes do not 
undergo the expected TNFα-induced apoptosis [3].  In accordance with this theory, it was 
hypothesized that inhibition of NF-κB in myoblasts would sensitize the cells to TNFα-
induced apoptosis, while the inhibition of NF-κB in myotubes would not sensitize the 
cells to TNFα-induced apoptosis.  To test this hypothesis, C2C12 IκBα-SR cells were 
treated with TNFα during various periods of skeletal muscle differentiation.   
As expected, undifferentiated IκBα-SR myoblasts saw a significant increase in 
cell death following TNFα treatment as seen by an increase in floating cells. (Figure B.2 - 
A).  IκBα-SR myoblast death was quantified following 24 hours of TNFα treatment 
(Figure B.2 - B), and a viability decrease of approximately 80% was seen in IκBα-SR 
myoblasts treated with TNFα concentrations between 5 ng/ml to 20 ng/ml.  A smaller 
decrease in repressor myoblast viability was seen using TNFα concentrations less than 5 
ng/ml (data not shown) indicating that 5 ng/ml was the minimum TNFα concentration 
required to get the maximum response.   
 To confirm that the increase in C2C12 IκBα-SR myoblast cell death elicited by 
TNFα treatment was in fact due to apoptosis, both a TUNEL assay and a Western blot for 
cleaved caspase-3 were performed.  The TUNEL assay is a chemical method for 
detecting DNA fragmentation, a characteristic trait of cell death.  IκBα-SR myoblasts 
treated with TNFα (5 ng/ml for 4 hours) showed TUNEL positive nuclei, as evidenced by 
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the colocalization of TUNEL and DAPI staining.  C2C12 Vector cells showed no positive 
TUNEL staining following TNFα treatment (Figure B.2 - C).   
Whole cell extracts of TNFα-treated Vector and IκBα-SR myoblasts were 
analyzed by Western blot.  Treated and untreated C2C12 Vector myoblasts presented 
with minimal levels of the apoptotic marker cleaved caspase-3, confirming the absence of 
cell death seen by other measures.  C2C12 IκBα-SR myoblasts exhibited a TNFα (5 
ng/ml for 4 hours) dependent increase in cleaved caspase-3 levels, consistent with what 
would be found in cells experiencing TNFα-induced apoptotic cell death [8, 17, 19] 
(Figure B.2 – D).   
 
 
3.3 - IκBα-SR myotubes are insensitive to TNFα-induced apoptosis. 
  
 Unlike their undifferentiated counterparts, C2C12 IκBα-SR myotubes exhibited 
no decrease in cell viability following TNFα treatment (Figure B.3).  Under phase 
microscopy, IκBα-SR myotubes exhibited no morphological changes following TNFα 
treatment of up to 20 ng/ml for 24 hours (Figure B.3 – A).  When quantified by cell 
count, there was no statistically significant change in cell viability; the slight decrease in 
IκBα-SR myotube viability was believed to be due to death from cells unable to 
differentiate in vitro.  TUNEL assays and cleaved caspase-3 westerns were carried out 
using C2C12 myotubes and results were negative for both Vector and IκBα-SR cell lines 
(Figure B.3 – C, D). 
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3.4 - Skeletal myotubes possess a functional TNFα signaling pathway. 
 
 To test the sensitivity of transfected C2C12 myotubes to TNFα, Western blot 
analysis was performed on protein lysates from TNFα-treated Vector and IκBα-SR 
myotubes.  The proteins of interest in this experiment were the phosphorylated forms of 
the mitogen-activated protein kinases (MAPKs) p38 and JNK.  The p38 and JNK 
signaling pathways are two intracellular cascades that are activated by TNFα via an NF-
κB independent manner [14].  In both Vector and IκBα-SR myotubes, TNFα treatment (5 
ng/ml) signals the activation of the p38 and JNK pathways as visualized by 
phosphorylated forms of the MAPKs (Figure B.4  - A).  The activation of these two 
signaling cascades by TNFα confirms that transfected C2C12 myotubes are sensitive to 
the inflammatory cytokine and that the absence of apoptosis in TNFα-treated IκBα-SR 
myotubes (Figure B.3) was not simply due to an absence of activation by TNFα.    
 TNFR1 sensitivity was confirmed functionally in differentiated C2C12 skeletal 
muscle cells using reverse transcriptase-polymerase chain reaction (RT-PCR).  Vector 
and IκBα-SR myotubes were treated with TNFα (5 ng/ml) for periods of 0, 2, and 4 
hours.  Total RNA was then collected from these cells, complimentary DNA (cDNA) was 
formed by reverse transcription, and PCR was carried out probing for cIAP transcript.  
cIAP is a NF-κB regulated anti-apoptotic protein [16, 20-21] and as a result, it can be 
seen to be up-regulated specifically in Vector myotubes following 4 hours of stimulation 
with TNFα.  The absence of cIAP up-regulation in IκBα-SR myotubes further confirms 
the inhibition of NF-κB in these cells (Figure B.4 – B). 
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3.5 - Skeletal muscle differentiation evokes a natural reduction of Apaf-1 
 Next, we set out to monitor the changes in Apaf-1 levels during differentiation.  
Using whole cell lysates of both C2C12 cell lines collected during the differentiation 
process (0, 24, 48, 72 hours DM), Western blot analysis probing for Apaf-1 was 
performed.  As shown previously [9], Apaf-1 levels decreased during the differentiation 
process and were almost completely ablated in terminally differentiated Vector myotubes 
(Figure B.5).  The differentiation marker myogenin was used to show that decreasing 
Apaf-1 levels corresponded with progression along the skeletal muscle differentiation 
program.  Interestingly, it was observed that this natural reduction of Apaf-1 was not 
dependent on NF-κB as the same reduction was seen in IκBα-SR cells (Figure B.5). 
 
3.6 - Over-expression of Apaf-1 does not rescue apoptosis in TNFα treated IκBα-SR 
myotubes. 
To test whether the reduction of the pro-apoptotic protein Apaf-1 was responsible 
for the NF-κB independent inhibition of apoptosis seen in IκBα-SR myotubes, the Apaf-1 
levels in these cells were restored using an expression plasmid and the cells were then 
treated with TNFα to see if apoptosis was rescued.  To restore Apaf-1 levels, IκBα-SR 
myoblasts were first transiently transfected with an Apaf-1 expression plasmid.  Then 
following transfection, the cells were allowed to differentiate for 72 hours.  Following 
differentiation, Apaf-1 over-expressing IκBα-SR myotubes were treated with TNFα (5 
ng/ml) for 4 hours.  Whole cell lysates from these cells were analyzed by Western blot 
analysis for cleaved caspase-3.  Unlike the previous study where the restoration of Apaf-1 
levels sensitized myotubes to cytochrome C induced apoptosis [9], the transiently 
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transfected Apaf-1 over-expressing IκBα-SR myotubes were not sensitized to TNFα-
induced apoptosis when compared with control pCDNA3 transfected IκBα-SR myotubes 
(Figure B.6).    
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CHAPTER 4 – DISCUSSON 
 
Using C2C12 myoblasts as an in vitro model of skeletal muscle, the data show 
that myotubes devoid of NF-κB activity (via stable expression of IκBα-SR) were equally 
resistant to TNFα-induced apoptosis as Vector myotubes (Figure B.3).  Furthermore, this 
NF-κB independent anti-apoptotic activity must arise during the differentiation process 
because myoblasts lacking NF-κB activity showed a significant sensitivity to TNFα 
through a substantial increase in cell death (Figure B.2).  Vector myoblasts experienced 
no decrease in cell viability, verifying that the transfection process was not responsible 
for the increased TNFα responsiveness of IκBα-SR myoblasts (Figure B.2).   
This increase in IκBα-SR myoblast cell death was due to apoptosis as signaled by 
TNFα, an inflammatory cytokine and known apoptotic factor [14].  Apoptosis was 
confirmed as the process responsible for the decrease in repressor myoblast viability via 
TUNEL assay and Western blot probing for the apoptotic marker cleaved caspase-3 
(Figure B.2 – C, D).   
The results further suggest that a down-regulation of TNFα signaling triggered by 
the onset of differentiation was not responsible for NF-κB independent mechanism of 
apoptotic resistance.  The phosphorylation of both p38 and JNK as well as the up-
regulation of cIAP transcription following TNFα treatment shows that C2C12 myotubes 
do receive the TNFα signal (Figure B.4).  The MAPK activation also suggests that 
C2C12 IκBα-SR myotubes exhibit fully functional TNF signaling pathways and that 
some cellular process independent of NF-κB must be inhibiting the apoptotic signal of 
TNFα. 
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A recent publication claims that skeletal muscle differentiation down-regulates 
the expression of Apaf-1, a component of the apoptosome complex responsible for 
caspase-9 activation, and prevents the post-mitotic cell from undergoing cytochrome C-
induced apoptosis [9].  Here we confirm that Apaf-1 levels are reduced during skeletal 
muscle differentiation and that this process occurs independently of NF-κB (Figure B.5).  
However, the over-expression of Apaf-1 in IκBα-SR myotubes was not enough to rescue 
sensitivity to TNFα-induced apoptosis (Figure B.6).   
Future studies have been proposed to investigate the expression levels of many 
anti- and pro-apoptotic proteins during the differentiation program.  It is hypothesized 
that skeletal muscle differentiation evokes changes in the expression levels of specific 
apoptotically relevant proteins in a way that promotes the survival of a myotube.  
Currently, we are beginning to investigate the Bcl-2 family of proteins.  The Bcl-2 family 
is a collection of proteins that regulate apoptosis through their control of mitochondrial 
outer membrane permeabilization and subsequent cytochrome C release [23].  This 
family contains both anti- (Bcl-2, Bcl-xL, Mcl-w, Bcl-w, A1) and pro-apoptotic (Bax, 
Bak) members that interact in equilibrium to decide the fate of a cell [23].  When this 
equilibrium is disturbed and the pro-apoptotic proteins outnumber the anti-apoptotic 
ones, a stressful stimulus like TNFα can trigger pores to form in the outer membrane of 
the mitochondria, allowing cytochrome C to enter the cytoplasm and bind with Apaf-1 to 
form the apoptosome [13].  A more in-depth examination of the Bcl-2 family could help 
elucidate a new pro-survival mechanism found in skeletal myotubes and possibly explain 
why Apaf-1 over-expressing IκBα-SR myotubes are insensitive to TNFα-induced 
apoptosis. 
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Although incomplete, the results here support the notion that skeletal muscle 
differentiation evokes the manifestation of an NF-κB independent mechanism of 
apoptotic resistance to TNFα treatment.  While there is currently no mechanism known to 
be responsible for this observation, it has been shown that the natural reduction of Apaf-1 
that occurs during the differentiation program does not confer this ability to the myotube.  
Studies are being undertaken to examine the possible role of other apoptotically relevant 
proteins with the hope that a mechanism responsible for this phenomenon be discovered 
in the very near future. Once complete, this mechanism would not only provide new 
insight into the cellular physiology of differentiated skeletal muscle, but could also lead 
to a new understanding of the role of NF-κB in rhabdomyosarcoma, a pediatric cancer 
characterized by tumors consisting of partially differentiated skeletal muscle cells [24-
26].   
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APPENDIX 
 
Appendix A – Diagrams 
 
Diagram A.1 – TNFα Signaling Pathways 
 
 
 
 
Diagram A.1 - TNFα-induced signaling. TNFα signals the apoptotic cascade through 
the cytoplasmic complex DISC (complex II), while also signaling the activation of the 
classical NF-κB pathway through membrane-bound complex I. NF-κB promotes the 
transcription of many anti-apoptotic genes which act to inhibit the apoptotic signal of 
TNFα through several mechanisms. 
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Diagram A.2 – Mechanism of NF-κB Inhibition by IκBα-SR 
 
 
 
Diagram A.2 – Mechanism of NF-κB Inhibition by IκBα-SR.  Expression of IκBα-SR 
inhibits NF-κB by trapping the transcription factor in the nucleus.  Because the 
mutant IκBα protein cannot be phosphorylated, it can not be degraded and NF-κB 
cannot reach the nucleus.  In the classical pathway, IκBα phosphorylation leads to 
proteasomal degradation of the protein and activation of NF-κB. 
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Appendix B – Figures 
 
Figure B.1 – Inhibition of NF-κB in C2C12 cell line via IκBα-SR Expression 
 
 
 
 
 
 
 
 
 
 
Figure B.1 - Inhibition of NF-κB in C2C12 cell line via IκBα-SR Expression.  (A) Gel 
shift of NF-κB activation by TNFα. Nuclear extracts were collected from TNFα-
treated C2C12 cells and a radioactive oligonucleotide probe was used to bind to 
activated nuclear NF-κB. (B) Luciferase reporter assay of NF-κB activity in Vector 
(control) and IκBα-SR myoblasts.  Lysate of transfected cells were collected and 
luminescence was measured following incubation with luciferin substrate.  
Luminescence was normalized for transfection efficiency using β-galactodiose assay 
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Figure B.2 – IκBα-SR myoblasts are sensitive to TNFα-induced apoptosis. 
 
 
 
 
 
Figure B.2 – IκBα-SR myoblasts are sensitive to TNFα-induced apoptosis.  (A) 
Cellular response to TNFα-treatment in Vector and IκBα-SR C2C12 myoblasts. 
Myoblasts were treated with TNFα (10 ng/ml) for 24 h; pictures were taken by phase 
microscopy. (B) TNFα-treated myoblast cell counts.  Equal numbers of cells were 
plated, treated with TNFα for 24 hours, and counted using a hemocytometer.  All 
counts normalized to untreated samples.  (C) TUNEL Assay of Vector and IκBα-SR 
C2C12 myoblasts.  Myoblasts were treated with TNFα (10 ng/ml) for 4 h; pictures 
were taken by fluorescence microscopy.  (D) Western blot for cleaved caspase-3. 
Vector and IκBα-SR C2C12 myoblasts were treated with TNFα (5 ng/ml) for 4 h; 
cellular extracts were probed for cleaved caspase-3 by Western blot analysis. 
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Figure B.3 – IκBα-SR myotubes are insensitive to TNFα-induced apoptosis. 
 
 
 
 
 
Figure B.3 – IκBα-SR myotubes are insensitive to TNFα-induced apoptosis.  (A) 
Cellular response to TNFα-treatment in Vector and IκBα-SR C2C12 myotubes. 
Myotubes were treated with TNFα (10 ng/ml) for 24 h; pictures were taken by phase 
microscopy. (B) TNFα-treated myotube cell counts.  Equal numbers of cells were 
plated and differentiated for 72 hours, then treated with TNFα for 24 hours, and 
counted using a hemocytometer.  All counts normalized to untreated samples.  (C) 
TUNEL Assay of Vector and IκBα-SR C2C12 myotubes.  Myotubes were treated with 
TNFα (10 ng/ml) for 4 h; pictures were taken by fluorescence microscopy.  (D) 
Western blot for cleaved caspase-3. Vector and IκBα-SR C2C12 myobubes were 
treated with TNFα (5 ng/ml) for 4 h; cellular extracts were probed for cleaved 
caspase-3 by Western blot analysis. 
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Figure B.4 – C2C12 myotubes possess a functional TNFα signaling pathway. 
 
 
 
 
 
 
 
 
 
 
 
Figure B.4 – C2C12 myotubes possess a functional TNFα signaling pathway.  (A) 
Western blot of proteins activated by TNFα treatment. Vector and IκBα-SR C2C12 
myotubes were treated with TNFα (5 ng/ml) for varying amounts of time and cellular 
extracts were probed for phosphorylated JNK (p-JNK) and p38 (p-p38) by Western 
blot analysis.  (B) Reverse transcriptase- polymerase chain reaction of TNFα-treated 
myotubes. Vector and IκBα-SR myotubes were treated with TNFα (5 ng/ml) for 2 and 
4 h. RNA was then isolated and PCR was carried out probing for cIAP transcript. 
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Figure B.5 – Skeletal muscle differentiation evokes a natural reduction of Apaf-1. 
 
 
 
 
 
 
 
  
 
 
 
Figure B.5 – Skeletal muscle differentiation evokes a natural reduction of Apaf-1.  
Apaf-1 protein expression levels in myoblasts and myotubes. Vector and IκBα-SR 
C2C12 cells grown in growth medium then switched to differentiation medium and 
collected every 24 h until terminal differentiation at 72 h.  Whole cell lysates from 
collected cells were probed for Apaf-1 and myogenin by Western blot analysis. 
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Figure B.6 – Over-expression of Apaf-1 does not rescue apoptosis in TNFα-treated 
IκBα-SR myotubes. 
 
 
 
 
 
 
 
 
 
Figure B.6 – Over-expression of Apaf-1 does not rescue apoptosis in TNFα-treated 
IκBα-SR myotubes.  C2C12 IκBα-SR myoblasts were transfected with either Apaf-1 
expression plasmid or control pCDNA3 plasmid and allowed to differentiated for 72 
h.  Transfected IκBα-SR myotubes were then treated with TNFα (5 ng/ml) for 4 h; 
whole cell lysates were collected and protein levels were analyzed by Western blot. 
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